Universal Vision Biotechnology Co Ltd Total Assets
Universal Vision Biotechnology Co Ltd total assets. Based on the latest financial reports, Universal Vision Biotechnology Co Ltd (3218) holds total assets worth NT$6.09 Billion TWD (≈ $191.97 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 3218 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Universal Vision Biotechnology Co Ltd (2003–2025)
Total assets of Universal Vision Biotechnology Co Ltd from 2003 to 2025. This chart illustrates how Universal Vision Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data. See Universal Vision Biotechnology Co Ltd stock quote for real-time trading data and today's change.
Universal Vision Biotechnology Co Ltd - Asset Composition Analysis
Universal Vision Biotechnology Co Ltd Total Assets Breakdown (December 2025)
Universal Vision Biotechnology Co Ltd total assets breakdown as of December 2025. Universal Vision Biotechnology Co Ltd's total assets of NT$6.09 Billion consist of 49.3% current assets and 50.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 12.8% |
| Accounts Receivable | NT$514.49 Million | 8.4% |
| Inventory | NT$303.63 Million | 5.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Universal Vision Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 3218 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Universal Vision Biotechnology Co Ltd's current assets represent 49.3% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 12.8% of total assets in 2025, down from 15.9% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 8.4% of total assets.
Universal Vision Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Universal Vision Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ramsay Health Care Ltd
AU:RHC
|
Australia | AU$21.70 Billion |
|
Encompass Health Corp
NYSE:EHC
|
USA | $7.46 Billion |
|
RAMSAY HLTH.CARE ADR/025
F:RMY0
|
Germany | €22.48 Billion |
|
Sienna Senior Living Inc
TO:SIA
|
Canada | CA$2.35 Billion |
|
Regis Healthcare Ltd
AU:REG
|
Australia | AU$2.11 Billion |
|
Pacific Smiles Group Ltd
AU:PSQ
|
Australia | AU$163.53 Million |
|
CareRx Corp
TO:CRRX
|
Canada | CA$243.16 Million |
|
Eifelhöhen-Klinik AG
F:EIF
|
Germany | €36.20 Million |
Universal Vision Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.92 | 2.61 | 1.71 |
| Quick Ratio | 2.62 | 2.34 | 1.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.97 Billion | NT$1.75 Billion | NT$701.88 Million |
Universal Vision Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Universal Vision Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.79 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | NT$6.09 Billion |
| Market Capitalization | $345.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Universal Vision Biotechnology Co Ltd's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Universal Vision Biotechnology Co Ltd's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Universal Vision Biotechnology Co Ltd (2003–2025)
The table below shows the annual total assets of Universal Vision Biotechnology Co Ltd from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$6.09 Billion ≈ $191.97 Million |
+5.73% |
| 2024-12-31 | NT$5.76 Billion ≈ $181.56 Million |
+12.32% |
| 2023-12-31 | NT$5.13 Billion ≈ $161.64 Million |
+13.87% |
| 2022-12-31 | NT$4.51 Billion ≈ $141.96 Million |
+20.17% |
| 2021-12-31 | NT$3.75 Billion ≈ $118.13 Million |
+18.32% |
| 2020-12-31 | NT$3.17 Billion ≈ $99.85 Million |
+19.72% |
| 2019-12-31 | NT$2.65 Billion ≈ $83.40 Million |
+26.25% |
| 2018-12-31 | NT$2.10 Billion ≈ $66.06 Million |
+4.62% |
| 2017-12-31 | NT$2.00 Billion ≈ $63.15 Million |
+15.01% |
| 2016-12-31 | NT$1.74 Billion ≈ $54.91 Million |
-7.79% |
| 2015-12-31 | NT$1.89 Billion ≈ $59.54 Million |
+4.84% |
| 2014-12-31 | NT$1.80 Billion ≈ $56.79 Million |
+32.03% |
| 2013-12-31 | NT$1.37 Billion ≈ $43.02 Million |
+8.65% |
| 2012-12-31 | NT$1.26 Billion ≈ $39.59 Million |
-9.17% |
| 2011-12-31 | NT$1.38 Billion ≈ $43.59 Million |
+36.86% |
| 2010-12-31 | NT$1.01 Billion ≈ $31.85 Million |
-9.58% |
| 2009-12-31 | NT$1.12 Billion ≈ $35.22 Million |
+2.57% |
| 2008-12-31 | NT$1.09 Billion ≈ $34.34 Million |
+54.70% |
| 2007-12-31 | NT$704.59 Million ≈ $22.20 Million |
+17.55% |
| 2006-12-31 | NT$599.41 Million ≈ $18.88 Million |
+56.23% |
| 2004-12-31 | NT$383.68 Million ≈ $12.09 Million |
+24.73% |
| 2003-12-31 | NT$307.60 Million ≈ $9.69 Million |
-- |
About Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical instruments, eyeglasses, contact lenses, and eyeglass accessories. It is also involved in eyeglasses optometry and dispensing services and leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy analysis, as we… Read more